中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2001年
2期
113-116
,共4页
血管滤泡性淋巴组织增生%Castleman's病%多中心%微小病灶%临床病理
血管濾泡性淋巴組織增生%Castleman's病%多中心%微小病竈%臨床病理
혈관려포성림파조직증생%Castleman's병%다중심%미소병조%림상병리
目的:探讨多中心血管滤泡性淋巴组织增生(MCD)的临床病理特征。方法:8例血管滤泡性淋巴组织增生(CD)经组织病理证实,并按Frizzera的标准病理分型为PC型、Mix型和HV型。MCD的诊断除了组织学为CD外,必须有至少一组淋巴结病变,并且行淋巴结广泛切除术。结果:淋巴结组织病理PC型6例(75%),Mix型1例,HV型1例。临床有系统性症状6例(75%);肝脾肿大3例(37.5%);术后6—66月复发5例(62.5%),其中1例(12.5%)发展为恶性淋巴瘤。结论:MCD倾向于复发进展潜在恶性的临床过程,其发病机制尚待进一步探讨;密切随访观察可早期发现微小病灶和继发的恶性病变;MCD者应选择多种模式的治疗方法。
目的:探討多中心血管濾泡性淋巴組織增生(MCD)的臨床病理特徵。方法:8例血管濾泡性淋巴組織增生(CD)經組織病理證實,併按Frizzera的標準病理分型為PC型、Mix型和HV型。MCD的診斷除瞭組織學為CD外,必鬚有至少一組淋巴結病變,併且行淋巴結廣汎切除術。結果:淋巴結組織病理PC型6例(75%),Mix型1例,HV型1例。臨床有繫統性癥狀6例(75%);肝脾腫大3例(37.5%);術後6—66月複髮5例(62.5%),其中1例(12.5%)髮展為噁性淋巴瘤。結論:MCD傾嚮于複髮進展潛在噁性的臨床過程,其髮病機製尚待進一步探討;密切隨訪觀察可早期髮現微小病竈和繼髮的噁性病變;MCD者應選擇多種模式的治療方法。
목적:탐토다중심혈관려포성림파조직증생(MCD)적림상병리특정。방법:8례혈관려포성림파조직증생(CD)경조직병리증실,병안Frizzera적표준병리분형위PC형、Mix형화HV형。MCD적진단제료조직학위CD외,필수유지소일조림파결병변,병차행림파결엄범절제술。결과:림파결조직병리PC형6례(75%),Mix형1례,HV형1례。림상유계통성증상6례(75%);간비종대3례(37.5%);술후6—66월복발5례(62.5%),기중1례(12.5%)발전위악성림파류。결론:MCD경향우복발진전잠재악성적림상과정,기발병궤제상대진일보탐토;밀절수방관찰가조기발현미소병조화계발적악성병변;MCD자응선택다충모식적치료방법。
Purpose:To study the clinical and pathological characteristics of multicentric angiofollicular lymph node hyperplasia (MCD).Methods:Eight patients with histologic diagnosis of angiofollicular lymph node hyperplasia (CD) were identified in the pathologic data base.The lymph node lesions were categorized as PC,Mix and HV types according to the criteria described by Frizzera. Patient with MCD had to have histology of CD within at least one regional group of lymph nodes and all underwent extensive lymphadenectomy.Results:The histologic features of 8 patients were six with PC,one with Mix and one with HV.Five patients presented with systemic symptoms. Three patients had splenomegaly and hapatomegaly. Five patients had local recurrence.Conclusions:MCD tends to recur and has a progressive clinical course with potential for malignancy ,and further study is needed to clarify the pathogenesis. Close follow-up and periodic surveillance are necessary to detect minimal disease and secondary malignant lesions. The patients with MCD should be candidates for multimodality therapy.